Liquid biopsy in glioblastoma: emerging technologies and translational opportunities.
A multimodal decision matrix and an artificial intelligence (AI)-driven fusion pipeline integrating fragmentomics, EV proteomics, and CTC transcriptomics are introduced to enhance minimal residual disease detection and guide precision neuro-oncology.